한글목차

약물 전달 및 유전자 전달 기기 시장은 2025년 21만 800달러, 2032년에는 45만 4,500달러에 이를 것으로 예측되며, 2025-2032년 CAGR은 11.6%를 나타낼 전망입니다.

약물 전달 및 유전자 전달 기기 부문에서는 세포, 조직, 생체의 단백질 발현 및 기능을 최종적으로 변화시키는 약물, 유전자, 유전자 산물의 개발 및 전달이 이루어집니다. 약물 전달 장치는 특정 투여 경로를 통해 약물을 전달하기 위해 사용되는 도구입니다. 반면, 유전자 전달은 DNA나 RNA와 같은 외래 유전물질을 숙주 세포에 도입하는 과정입니다.

시장 역학

감염성 질환, 심혈관 질환, 암, 당뇨병과 같은 만성 질환의 부담 증가, 약물 전달 및 유전자 전달 기기에 대한 수요 증가, 세포 치료 및 유전자 치료에 대한 자금 지원 증가, 유전자 치료 승인 증가는 예측 기간 동안 세계 약물 전달 및 유전자 전달 기기 시장의 성장을 증가시킬 것으로 예상되는 주요 요인으로 예상됩니다.

예를 들어, 2022년 11월 이뮤논과 Acuitas Therapeutics는 이뮤논의 PLACCINE 핵산 백신 구조물과 Acuitas의 독자적인 지질 전달 기술의 조합을 평가하기 위한 계약을 체결했습니다. 이번 계약에 따라 이뮤논은 Acuitas의 다양한 LNP 제형에 제형화된 벡터 구조물을 투여하여 마우스 모델에서 유전자 발현 및 면역원성을 평가할 예정입니다.

본 조사의 주요 특징

• 이 보고서는 2024년을 기준 연도로 하여 2025-2032년까지의 예측 기간 동안 시장 규모와 연평균 성장률(CAGR%)을 제공하는 세계 약물 전달 및 유전자 전달 기기 기기 시장을 상세하게 분석하여 예측한 보고서입니다.
• 또한, 다양한 부문에 걸친 잠재적 수익 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
• 또한 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략 등에 대한 중요한 고찰을 제공합니다.
• 이 보고서는 기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 재무 성과, 전략 등의 매개 변수를 기반으로 세계 약물 전달 및 유전자 전달 기기 시장의 주요 업체를 프로파일링합니다.
• 이 보고서의 통찰력을 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 유형화, 시장 확대, 마케팅 전술에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.
• 세계 약물 전달 및 유전자 전달 기기 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 시장 진출기업, 재무 분석가 등 이 산업의 다양한 이해관계자를 대상으로 합니다.
• 이해관계자들은 세계 약물 전달 및 유전자 전달 기기 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있습니다.

목차

제1장 조사 목적과 전제조건

• 조사 목적
• 전제조건
• 약어

제2장 시장 전망

• 보고서 설명
  • 시장 정의와 범위
• 주요 요약
• Coherent Opportunity Map(COM)

제3장 시장 역학, 규제, 동향 분석

• 시장 역학
• 영향 분석
• 규제 시나리오
• 제품 발매 및 승인
• PEST 분석
• Porter's Five Forces 분석
• 인수합병(M&A) 시나리오

제4장 세계의 약물 전달 및 유전자 전달 기기 시장 - 코로나바이러스(COVID-19) 팬데믹의 영향

• COVID-19 역학
• 공급측과 수요측 분석
• 경제에 대한 영향

제5장 세계의 약물 전달 및 유전자 전달 기기 시장, 제품별, 2020-2032년

• 서론
• 망막하 주입 캐뉼라
• 연장 튜브
• 정맥 카테터
• 멸균 인슐린 주사기
• 프리필드 시린지
• 수액 백

제6장 세계의 약물 전달 및 유전자 전달 기기 시장, 시판약별, 2020-2032년

• 서론
• Luxturna
• Yescarta
• Zolgensma
• Kymriah
• Provenge
• Strimvelis

제7장 세계의 약물 전달 및 유전자 전달 기기 시장, 지역별, 2020-2032년

• 서론
• 북미
• 라틴아메리카
• 유럽
• 아시아태평양
• 중동
• 아프리카

제8장 경쟁 구도

• Pfizer, Inc.
• Novartis AG
• Kite Pharma, Inc.
• Bluebird bio, Inc.
• Vericel Corporation
• uniQure N.V.
• Spark Therapeutics, Inc.
• Renova Therapeutics
• Orchard Therapeutics plc
• Kolon Tissue Gene, Inc.
• Human Stem Cell Institute
• Amgen, Inc.
• Dendreon Pharmaceuticals
• Helixmith Co.
• Bausch & Lomb Incorporated, Ltd.(ViroMed Co., Ltd.)
• Becton Dickinson and Company
• Castle Creek Biosciences, Inc.(Fibrocell Technologies, Inc.)

제9장 섹션

• 조사 방법
• 출판사에 대해

영문목차

Drug and Gene Delivery Devices Market is estimated to be valued at USD 210.8 Thousand in 2025 and is expected to reach USD 454.5 Thousand by 2032, growing at a compound annual growth rate (CAGR) of 11.6% from 2025 to 2032.

The field of drug and gene delivery involves the development and delivery of drugs, genes, and/or gene products that ultimately alter protein expression and function of the cells, tissues, and living organisms. Drug delivery devices are the tools used to deliver the drug through the specific route of administration. While, gene delivery is the process of introducing foreign genetic material, such as DNA or RNA, into host cells.

Market Dynamics:

Rise in burden of chronic diseases, such as infectious disease, cardiovascular disease, cancer, and diabetes, increasing demand for drug or gene delivery devices, increasing funding for cell and gene therapies, and rise in approvals for gene therapies are major factors expected to augment the growth of the global drug and gene delivery devices market over the forecast period.

For instance, in November 2022, Imunon, Inc. and Acuitas Therapeutics signed an agreement to evaluate the combination of IMUNON's PLACCINE nucleic acid vaccine constructs formulated with Acuitas' proprietary lipid delivery technology. Under the agreement, IMUNON will evaluate administration of its vector constructs formulated in various Acuitas LNP formulations for gene expression and immunogenicity in murine models.

Key features of the study:

• This report provides in-depth analysis of the global drug and gene delivery devices market, and provides market size (US$ Thousand) and compound annual growth rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global drug and gene delivery devices market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Pfizer, Inc., Novartis AG, Kite Pharma, Inc., Bluebird bio, Inc., Becton, Amgen, Inc., Vericel Corporation, uniQure N.V., Spark Therapeutics, Inc., Renova Therapeutics, Orchard Therapeutics plc, Kolon Tissue Gene, Inc., Human Stem Cell Institute, Dendreon Pharmaceuticals, Dickinson and Company, Helixmith Co., Ltd (ViroMed Co., Ltd), Bausch & Lomb Incorporated, and Castle Creek Biosciences, Inc (Fibrocell Technologies, Inc.), among others.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global drug and gene delivery devices market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global drug and gene delivery devices market.

Detailed Segmentation:

• Global Drug and Gene Delivery Devices Market, By Product:
  • Sub-retinal Injection Cannula
  • Extension Tube
  • Intravenous Catheter
  • Sterile Insulin Syringe
  • Pre-filled Syringe
  • Infusion Bags
• Global Drug and Gene Delivery Devices Market, By Commercialized Drugs:
  • Luxturna (Drug Delivery Devices)
  • Yescarta (Drug Delivery Devices)
  • Zolgensma (Drug Delivery Devices)
  • Kymriah (Drug Delivery Devices)
  • Provenge (Drug Delivery Devices)
  • Strimvelis (Drug Delivery Devices)
• Global Drug and Gene Delivery Devices Market, By Region:
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa
• Company Profiles:
  • Pfizer, Inc.
  • Novartis AG
  • Kite Pharma, Inc.
  • Bluebird bio, Inc.
  • Becton Dickinson and Company
  • Amgen, Inc.
  • Vericel Corporation
  • uniQure N.V.
  • Spark Therapeutics, Inc.
  • Renova Therapeutics
  • Orchard Therapeutics plc
  • Kolon Tissue Gene, Inc.
  • Human Stem Cell Institute
  • Dendreon Pharmaceuticals
  • Helixmith Co., Ltd (ViroMed Co., Ltd.)
  • Bausch & Lomb Incorporated
  • Castle Creek Biosciences, Inc. (Fibrocell Technologies, Inc.)

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Product
  • Market Snapshot, By Commercialized Drugs
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Rise in burden of chronic diseases across the globe
  • Stringent rules and regulations
  • Increasing demand for drug and gene delivery devices
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product launch/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario

4. Global Drug and Gene Delivery Devices Market - Impact of Coronavirus (COVID-19) Pandemic

• COVID-19 Epidemiology
• Supply Side and Demand Side Analysis
• Economic Impact

5. Global Drug and Gene Delivery Devices Market, By Product, 2020-2032, (US$ Thousand)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021-2032
  • Segment Trends
• Sub-retinal Injection Cannula
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Thousand)
• Extension Tube
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Thousand)
• Intravenous Catheter
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Thousand)
• Sterile Insulin Syringe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Thousand)
• Pre-filled Syringe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Thousand)
• Infusion Bags
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Thousand)

6. Global Drug and Gene Delivery Devices Market, By Commercialized Drugs, 2020-2032, (US$ Thousand)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021-2032
  • Segment Trends
• Luxturna (Drug Delivery Devices)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Thousand)
• Yescarta (Drug Delivery Devices)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Thousand)
• Zolgensma (Drug Delivery Devices)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Thousand)
• Kymriah (Drug Delivery Devices)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Thousand)
• Provenge (Drug Delivery Devices)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Thousand)
• Strimvelis (Drug Delivery Devices)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Thousand)

7. Global Drug and Gene Delivery Devices Market, By Region, 2020-2032, (US$ Thousand)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021-2032
  • Segment Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product, 2020-2032,(US$ Thousand)
  • Market Size and Forecast, and Y-o-Y Growth, By Commercialized Drugs, 2020-2032,(US$ Thousand)
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product, 2020-2032,(US$ Thousand)
  • Market Size and Forecast, and Y-o-Y Growth, By Commercialized Drugs, 2020-2032,(US$ Thousand)
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product, 2020-2032,(US$ Thousand)
  • Market Size and Forecast, and Y-o-Y Growth, By Commercialized Drugs, 2020-2032,(US$ Thousand)
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product, 2020-2032,(US$ Thousand)
  • Market Size and Forecast, and Y-o-Y Growth, By Commercialized Drugs, 2020-2032,(US$ Thousand)
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product, 2020-2032,(US$ Thousand)
  • Market Size and Forecast, and Y-o-Y Growth, By Commercialized Drugs, 2020-2032,(US$ Thousand)
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product, 2020-2032,(US$ Thousand)
  • Market Size and Forecast, and Y-o-Y Growth, By Commercialized Drugs, 2020-2032,(US$ Thousand)

8. Competitive Landscape

• Pfizer, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Novartis AG
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Kite Pharma, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Bluebird bio, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Vericel Corporation
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• uniQure N.V.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Spark Therapeutics, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Renova Therapeutics
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Orchard Therapeutics plc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Kolon Tissue Gene, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Human Stem Cell Institute
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Amgen, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Dendreon Pharmaceuticals
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Helixmith Co.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Bausch & Lomb Incorporated, Ltd. (ViroMed Co., Ltd.)
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Becton Dickinson and Company
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Castle Creek Biosciences, Inc. (Fibrocell Technologies, Inc.)
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Analyst Views

9. Section

• Research Methodology
• About us